The Nordic Lung Cancer Symposium is an important meeting place for clinicians and scientists in lung cancer to exchange knowledge, experience and ideas, and to promote collaboration and networking. It is a meeting where young and established clinicians and scientists in lung cancer meet across the borders. The scientific program is developed by representatives from the lung cancer group in each of the countries; Eeva-Maija Nieminen (Finland), Jens Benn Sørensen (Denmark), Signe Friesland (Sweden), and Odd Terje Brustugun (Norway). The program focuses on clinical topics that are relevant for doctors and scientists working in lung cancer in the Nordic countries.

The early bird registration is open until March 1st! https://nlcs2020.com/registration/
You can register later, fee will increase though.
The program is attached, and you can view it here: https://nlcs2020.com/program/

Abstracts covering basic, and translational and clinical science that contribute to the understanding of lung cancer in broad terms are eligible for submission. We also encourage abstracts reporting interesting cases in lung cancer. The abstract submission deadline is March 15th. https://nlcs2020.com/abstract/

Organized by Marianne Aanerud (N), Odd Terje Brustugun (N), Jens Benn Sørensen (DK), Signe Friesland (S), and Eeva-Maija Nieminen (SF).
Programme
14th Nordic Lung cancer symposium 2020
Bergen, Norway May, 7th - 10th, 2020

THURSDAY MAY 7 2020

17.00-18.00 REGISTRATION

18.00-20.00 SATELLITE SYMPOSIUM (Topic: Targeted therapy)
Chairman: TBC
Sponsored by: Takeda

RECEPTION BY THE MUNICIPALITY OF BERGEN

FRIDAY MAY 8 2020

08.30-9.00 WELCOME, PROGRAMME OVERVIEW
Marianne Aanerud, Odd Terje Brustugun (N),
Eeva-Maija Nieminen (SF), Jens Benn Sørensen (DK),
Signe Friesland (S)

09.00-10.20 LUNG CANCER DIAGNOSIS AND SCREENING
Chairman: Zaighem Saghir (DK)

Presentations 15 minutes followed by 5 minutes discussion

09.00 LUNG CANCER SCREENING: Who should be screened? Implementation issues in Nordic countries?
Haseem Ashraf (N)

09.20 BLOOD BASED SCREENING
Åslaug Helland (N)

09.40 SCREENING EXPERIENCE FROM SWEDEN
Hirsh Koyi (S)

10.00 RESULTS FROM THE NORWEGIAN LUNG CANCER REGISTRY
Lars Fjellbirkeland (N)

10.20-10.50 COFFEE BREAK, EXHIBITION, AND POSTERS

10.50-12.15 EARLY STAGE LUNG CANCER
Chairman: Ravichandra Ravi (SF)

Presentations 15 minutes followed by 5 minutes discussion

10.50 ARE ROBOTS HERE TO STAY?
Rune Eggum (N)

11.30 FOLLOW-UP OF SMALL NODULES – BEST PRACTICE?
Eeva-Maija Nieminen (SF)

11.50 IO IN RESECTABLE AND IN LOCALLY ADVANCED NSCLC, BOTH SINGLE AGENTS AND COMBOS?
Bjørn Henning Grønberg (N)
14th NTOG Biannually Lung Cancer Symposium

12.15-13.15 SATELLITE SYMPOSIUM (TOPIC: Immuno-oncology)
Chairman: TBC
Sponsored by: MSD

13.15-14.45 LUNCH AND EXHIBITION, POSTERS

15.45-16.30 LOCALLY ADVANCED NSCLC
Chairman: Signe Friesland (S)
Presentations 15 minutes followed by 5 minutes discussion

15.45 SBRT IN OLOGOMETASTATIC DISEASE – ANY LIMITS?
Luigi de Petris (S)
16.05 IMMUNORADIOThERAPY – A DANGEROUS ENDEAVOR?
Andreas Hallquist (S)

DINNER

SATURDAY MAY 9 2020

8.30-10.15 ONCOGENE DRIVEN NSCLC
Chairman: Odd Terje Brustugun (N)
Presentations 15 minutes followed by 5 minutes discussion

08.30 SMALLER AND SMALLER TREATMENT GROUPS - HOW TO IMPLEMENT DIAGNOSIS AND TREATMENT?
Simon Ekman (S)
08.50 CLINICAL ALK EXPERIENCE
Marianne Aanerud (N)
09.10 INTRODUCTION OF “EXPENSIVE DRUGS” – HOW TO LEARN FROM EACH OTHER TBC - (S)
09.30 EGFR INTRINSIC AND ACQUIRED RESISTANCE MECHANISMS
Eric Santoni-Ruggiu (DK)
09.50 TIME FOR ROUTINE USE OF NGS IN THE INITIAL DIAGNOSTIC PROCESS IN NSCLC?
Jussi Koivonen (SF)

10.15-10.45 COFFEE BREAK, EXHIBITION, AND POSTERS

10.45-12.15 SATELLITE SYMPOSIUM (topic: novel diagnostics)
Chairman: TBC
Sponsored by: AstraZeneca

12.15-13.15 LUNCH

13.15-14.15 ORAL PRESENTATIONS OF BEST ABSTRACTS

14.15-15.35 IMMUNO-ONCOLOGY
Chairman: Jens Benn Sørensen (DK)
Presentations 15 minutes followed by 5 minutes discussion

14.15 PD-L1, TUMOR MUTATIONAL BURDEN; AND OTHER MARKERS FOR IMMUNOTHERAPY
Henric Hager (DK)
14.35 OPTIMAL COMBINATIONS OF IO
14th NTOG Biannually Lung Cancer Symposium

14.55 THE FINNISH EXPERIENCE
Sanna Livanainen - (SF)

15.15 LONG-TERM EXPERIENCE OF IO IN CLINICAL PRACTICE
Øystein Flatten (N)

15.35-16.00 COFFEE BREAK, EXHIBITION, POSTERS

16.00-17.00 BREAKOUT SESSIONS

A: LUNG CANCER SCREENING - CLINICAL EXPERIENCES IN NORDIC COUNTRIES
Chairman: Hirsh Koyi (S)

B: IMPLEMENTATION OF EXPENSIVE DRUGS – LEARNING FROM EACH OTHER
Jussi Koivonen (N)

C: CLINICAL AND REGISTRY RESEARCH – POSSIBILITIES FOR NORDIC COLLABORATION
Ravichandra Ravi (SF) and Bjørn Henning Grønberg (NO)

D: PALLIATIVE CARE
Margrethe Aase Schauffel (N)

17.00 -17.30 FEEDBACK FROM BREAK-OUT SESSIONS
DINNER

SUNDAY MAY 10 2020

09.00-09.45 SPECIAL TOPICS IN LUNG CANCER
Chairman Eeva-Maija Nieminen (SF)

09.00 PATIENT REPORTED OUTCOME (PRO) IN RELATION TO LUNG CANCER
Chairman: Rasmus Blechingberg Friis (DK)

09.20 PALLIATION IN THE ERA OF SO MANY TREATMENT POSSIBILITIES – HOW TO SAY “NOT MORE”
Eeva-Maija Nieminen (SF)

09.45-10.30 COFFEE, EXHIBITION, AND POSTERS

10.30-12.20 SCLC AND MESOTHELIOMA
Chairman: Jens Benn Sørensen (DK)
Five minutes discussion after each presentation

10.30 SCLC – IMMUNOTHERAPY AND OTHER APPROACHES
Tine Schytte (DK)

10.50 SURGERY in SCLC – TOO OFTEN OR TOO SELDOM?
Bengt Bergman (S)

11.10 SHOULD WE CONTINUE TO PROVIDE PCI IN SCLC?
Jan Nyman (S)

11.35 WHERE ARE WE MOVING IN MALIGNANT MESOTHELIOMA
Ronny Öhman (S)

12.00 UPDATES ON SURGERY IN MESOTHELIOMA
Philip Ryom (DK)

12.30 LUNCH AND ADJOURN